A clinical trial of dexmedetomidine or remifentanil sedation for awake fibreoptic intubation

Status

Terminated

Phases

Phase 3

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12605000231640

Acronym

STOPIT

Enrollment

Registered

2005-08-26

Start date

2004-11-30

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Dexmedetomidine 0.7 mcg/kg then 0.4 mcg/kg/h until completion of procedure

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Treatment

Masking

Blinded (masking used)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Awake fibreoptic intubation, no contraindication to remifentanil or dexmedetomidine.

Exclusion criteria

Chronic alpha-2 agonist or opioid therapy, allergy or previous adverse reaction to study drugs, uncontrolled hypertension, heart <50, 2nd or 3rd degree heart block, severe ventricular, renal, hepatic or respiratory dysfuction, pregnancy or lactation.

Outcome results